Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
elranatamab + inobrodib
- Development stage
- Unknown
- Lead developer
- CellCentric
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Subcutaneous, Oral
01
Overview
elranatamab + inobrodib is a combination therapy being investigated for the treatment of various hematological malignancies. It consists of elranatamab (PF-06863135), a humanized bispecific antibody that targets B-cell maturation antigen (BCMA) on myeloma cells and CD3 on T cells, and inobrodib (CCS1477), an oral small molecule inhibitor of the p300 and CBP bromodomains. Developed by CellCentric in collaboration with Pfizer (the originator of elranatamab), this combination is being evaluated in the Phase 1/2a NCT04068597 trial. The rationale for the combination lies in inobrodib's ability to downregulate key oncogenic drivers like MYC and IRF4, potentially enhancing the efficacy of the T-cell engager elranatamab in relapsed/refractory multiple myeloma and other blood cancers.
- Brand names
- Elrexfio
- Other names
- inobrodib + elranatamabCCS1477 + elranatamab
02
Targets
BCMA (B-cell maturation antigen)CD3 (T-cell surface glycoprotein CD3)CREBBP BD (Creb-binding protein bromodomain)EP300 BD (E1A Binding Protein p300 Bromodomain)
Beyond the preview
Go deeper on elranatamab + inobrodib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on elranatamab + inobrodib.